Baxdela® (delafloxacin) – New indication
October 24, 2019 - Melinta Therapeutics announced the FDA approval of Baxdela (delafloxacin) tablets and injection, for the treatment of adult patients with community-acquired bacterial pneumonia, (CABP) caused by susceptible microorganisms,
Streptococcus pneumoniae, Staphylococcus aureus (methicillin- susceptible isolates only), Klebsiella pneumoniae, Escherichia coli, Pseudomonas aeruginosa, Haemophilus influenzae, Haemophilus parainfluenzae, Chlamydia pneumoniae, Legionella pneumophila, and Mycoplasma pneumoniae.
Top